Amicus Therapeutics CEO Sells Shares

TradingView
2025.12.04 01:20
portai
I'm PortAI, I can summarize articles.

Reporter NameCampbell Bradley LRelationshipPresident and CEO, 10% OwnerTypeSellAmount$146,011SEC FilingForm 4Bradley L. Campbell, President and CEO of Amicus Therapeutics, and a 10% owner, sold 14,587 shares of common stock on December 1, 2025, at a weighted average price of $10.0097 per share, totaling $146,011. Following the transaction, Campbell directly owns 1,137,282 shares of the company. The sale was executed under a Rule 10b5-1 trading plan adopted on September 13, 2024.SEC Filing: AMICUS THERAPEUTICS, INC. [ FOLD ] - Form 4 - Dec. 03, 2025

Reporter NameCampbell Bradley L
RelationshipPresident and CEO, 10% Owner
TypeSell
Amount$146,011
SEC FilingForm 4

Bradley L. Campbell, President and CEO of Amicus Therapeutics, and a 10% owner, sold 14,587 shares of common stock on December 1, 2025, at a weighted average price of $10.0097 per share, totaling $146,011. Following the transaction, Campbell directly owns 1,137,282 shares of the company. The sale was executed under a Rule 10b5-1 trading plan adopted on September 13, 2024.

SEC Filing: AMICUS THERAPEUTICS, INC. [ FOLD ] - Form 4 - Dec. 03, 2025

Source: TradingView The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2025 Longbridge｜Disclaimer